Stay updated on Pembrolizumab and Itacitinib for NSCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab and Itacitinib for NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab and Itacitinib for NSCLC Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.2 to v3.8.0. The page still displays a 403 Forbidden error instead of the study record.
    Difference
    0.2%
    Check dated 2026-10-29T22:14:41.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    A sitewide NIH banner announces a transition in terminology from “Artificial Intelligence” to “Super Intelligence.” The study record remains inaccessible behind a 403 error.
    Difference
    1%
    Check dated 2026-10-22T22:50:04.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    The footer’s site revision identifier changed from v3.7.1 to v3.7.2; the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-15T22:01:38.000Z thumbnail image
  4. Check
    26 days ago
    Change Detected
    Summary
    The footer’s ClinicalTrials.gov revision label changes from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-08T22:08:02.000Z thumbnail image
  5. Check
    40 days ago
    Change Detected
    Summary
    The study record page now returns a 403 Forbidden error, replacing the detailed study information with an access-denied message. This blocks viewing the record and its related materials on the page.
    Difference
    18%
    Check dated 2026-09-24T21:36:16.000Z thumbnail image
  6. Check
    47 days ago
    Change Detected
    Summary
    Revision: v3.7.0 appears on the page, replacing Revision: v3.6.6. This reflects an internal update to the page's revision/versioning, not a change to the study content presented to users.
    Difference
    0.1%
    Check dated 2026-09-17T22:04:51.000Z thumbnail image

Stay in the know with updates to Pembrolizumab and Itacitinib for NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Itacitinib for NSCLC Clinical Trial page.